Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) EBITDA Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBITDA Margin for 4 consecutive years, with 20.25% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 642381.0% to 20.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 157.38% through Dec 2025, up 215354.0% year-over-year, with the annual reading at 157.38% for FY2025, 215354.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 20.25% at Orchestra BioMed Holdings, up from 2415.68% in the prior quarter.
  • The five-year high for EBITDA Margin was 20.25% in Q4 2025, with the low at 6403.56% in Q4 2024.
  • Average EBITDA Margin over 4 years is 2109.41%, with a median of 2006.39% recorded in 2024.
  • The sharpest move saw EBITDA Margin tumbled -398212bps in 2023, then skyrocketed 642381bps in 2025.
  • Over 4 years, EBITDA Margin stood at 884.68% in 2022, then plummeted by -450bps to 4866.79% in 2023, then tumbled by -32bps to 6403.56% in 2024, then soared by 100bps to 20.25% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 20.25%, 2415.68%, and 2318.66% for Q4 2025, Q3 2025, and Q2 2025 respectively.